Metabolic stability and antigenic modulation of nicotinic acetylcholine receptors on bovine adrenal chromaffin cells by unknown
Metabolic Stability and Antigenic Modulation of 
Nicotinic Acetylcholine Receptors on 
Bovine Adrenal Chromaflin Cells 
Linda S. Higgins and Darwin K. Berg 
Department of  Biology,  University  of  California, San Diego, La Jolla, California  92093 
Abstract.  Bovine adrenal chromaftin ceils have nico- 
tinic acetylcholine receptors (AChRs)  that are activated 
by the splanchnic nerve, resulting in release of 
catecholamines from the cells. Examination of the 
AChRs can provide information about the regulation 
and turnover of synaptic components on neurons and 
endocrine cells. Previous studies have shown that mAb 
35 recognizes the AChR on the cells. Here we show 
that mAb 35 can remove AChRs from the surface of 
the cells by antigenic modulation, and that the modu- 
lation can be used together with other methods to ex- 
amine the stability and turnover of the receptors in the 
plasma membrane. Unexpectedly, the results indicate a 
disparity between the rate at which AChRs reappear 
on the cells and the rate at which the ACh response 
recovers  after preexisting AChRs have been removed. 
Exposure of bovine adrenal chromaffin cultures to 
mAb 35 results in a parallel decrease in the magnitude 
of the nicotinic response and the number of AChRs on 
the cells. The decrease depends on the concentration 
and divalence of mAb 35, and on the time and tem- 
perature of the incubation. The antibody induces 
receptor aggregation in the plasma membrane under 
conditions where receptor loss subsequently occurs. 
After binding to receptor,  mAb 35 appears to be inter- 
nalized, degraded, and released from the cells through 
a temperature sensitive pathway that requires 
lysosomal function. These features are characteristic of 
antigenic modulation. 
Appearance of new AChRs on the cells either after 
antigenic modulation or after blockade of existing 
AChRs with monovalent antibody fragments occurs at 
a rate equivalent to 3 % of the receptors present on 
control cells per hour. The rate of receptor loss from 
the cells was measured in the presence of either 
tunicamycin or puromycin to block appearance of new 
receptors.  Both conditions indicated a receptor half-life 
of ~o 24 h and a rate of loss of ,,o 3 %/h. The finding 
that the rate of receptor loss equaled the rate of recep- 
tor appearance was consistent with the observation that 
the total number of AChRs on untreated cells did not 
increase with time. In the presence of tunicamycin, 
loss of receptor-mediated response to nicotine also oc- 
curred with a half-time of 24 h. Paradoxically, the rate 
of recovery of the nicotinic response, determined using 
two procedures, was more than twice as great as the 
rate at which new AChRs appeared on the cells. The 
disparity was not generated by the existence of "spare" 
receptors or by differences in the time course or con- 
centration dependence of the response to agonist. In- 
stead the results suggest differences in the activity of 
new and old AChR populations in the plasma mem- 
brane. 
M 
UCH of what is presently known about the regula- 
tion and turnover of synaptic components comes 
from studies of  the vertebrate neuromuscular junc- 
tion, where the best characterized  component by far is the 
nicotinic  acetylcholine  receptor  (AChR)  I.  With the recent 
advent of  probes for neuronal AChRs, it has become possible 
to carry out comparative studies to determine the extent to 
which regulatory  features of the muscle AChR can be ex- 
1. Abbreviations  used in this paper: AChR, nicotinic acetylcholine receptor; 
BrACh, bromoacetyicholine;  DTNB, 5,5-dithio-bis(2-nitrobenzoate);  lab, 
fragment  of mAb retaining  the antigen binding  site;  3H-NE,  3H-norepi- 
nephrine. 
tended to neurotransmitter  receptors at other synapses. Ini- 
tial results suggest certain differences between neuronal and 
muscle AChRs with respect to receptor structure (Boulter et 
al.,  1986, 1987; Whiting and Lindstrom, 1986, 1987) and 
regulation (Baccaglini and Cooper, 1982; Brenner and Mar- 
tin, 1976; Dunn and Marshall,  1985; Jacob and Berg, 1987, 
1988; Tuttle, 1983). The differences may extend to the man- 
ner in which cell-cell interactions influence the function of 
AChRs in the plasma membrane (Margiotta et al., 1987a, b). 
A promising  system for gaining more information about 
neuronal AChRs is provided by adrenal chromalfin cells in 
culture. AChRs on adrenal chromaffin cells are likely to be 
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crest as do sympathetic neurons, and, like sympathetic neu- 
rons, the ceils receive synaptic input from spinal cord neu- 
rons, generate action potentials, and synthesize and secrete 
catecholamines and neuropeptides (see Livett, 1984 for re- 
view). The pharmacology (Higgins and Berg, 1987,  1988a) 
and single channel properties (Fenwick et al.,  1982) of bo- 
vine adrenal chromaffin AChRs suggest similarities to neu- 
ronal AChRs.  We have previously demonstrated that several 
probes can be used to examine AChRs on bovine adrenal 
chromaffin cells (Higgins and Berg,  1987,  1988a).  One of 
these is mAb 35,  a  mAb raised against AChR from Elec- 
trophorus electric organ that recognizes the main immuno- 
genic region of muscle and electric organ AChRs (Tzartos et 
al., 1981) and cross reacts with chick ciliary ganglion AChRs 
(Halvorsen and Berg, 1987). A second is neuronal bungaro- 
toxin, a  protein toxin from the venom of Bungarus multi- 
cinctus that reversibly blocks neuronal AChRs (Ravdin  and 
Berg, 1979) and is distinct from ct-bungarotoxin. Neuronal 
bungarotoxin has  previously been referred to as bungaro- 
toxin 3.1, toxin F, and K-bungarotoxin (Loring and Zigmond, 
1988).  A  third probe for AChRs  on bovine adrenal chro- 
maffin cells is the agonist nicotine which binds with high 
affinity to a desensitized form of the receptor (Higgins and 
Berg,  1988a). 
Here we show that chronic exposure of the cells to mAb 
35 causes loss of the surface AChRs through antigenic modu- 
lation. We then take advantage of the modulation and other 
manipulations to demonstrate that the normal metabolic sta- 
bility of AChRs in the plasma membrane is similar to that 
previously described for AChRs  on skeletal muscle (Dev- 
reotes and Fambrough,  1975;  Devreotes et al.,  1977)  and 
chick ciliary ganglion neurons (Stollberg and Berg, 1987) in 
culture. Unexpectedly, we find a substantial discrepancy be- 
tween the  rate at which receptors reappear in the plasma 
membrane after antigenic modulation and the rate at which 
recovery of the nicotinic response is obtained. The results 
suggest a difference in the functional properties of new and 
old  AChRs  in  the  plasma  membrane.  This  hypothesis  is 
explored further in the accompanying paper where a cAMP- 
dependent process is  shown to enhance the functional re- 
sponse of old AChRs but not new AChRs in the plasma mem- 
brane (Higgins and Berg,  1988b). 
Materials and Methods 
Cell Cultures 
Bovine adrenal chromaffin cell cultures were prepared as previously de- 
scribed (Higgins and Berg, 1987).  Briefly, bovine adrenal glands were ob- 
tained  from  a  local  slaughter  house,  and  medullary cells were  isolated 
mechanically  and  enzymatically,  using  0.2%  (wt/vol)  collagenase  and 
0.015%  (wt/vol) DNase. Chromaffin cells were purified on a Percoll gra- 
dient and plated at a density of 5  ×  105 cells/16-mm well in DME contain- 
ing 10% FBS, 50 U/ml penicillin G, and 50 p.g/ml streptomycin. Cultures 
were maintained at 35°C in 5% CO2/95%  air and received fresh medium 
every 2 d, with  10  -5 M cytosine arabinoside being included after the first 
48 h. 
mAb 35 Binding 
~"51-mAb 35 binding was determined as previously described (Higgins and 
Berg, 1987; Higgins and Berg, 1988a).  Binding to intact cells was measured 
by incubating cultures with 5 nM ~:51-mAb 35 for 60 min at 37°C, washing 
4 times in a 2-min period, scraping in 0.6 N NaOH, and analyzing for radio- 
activity.  Binding to  AChRs  in  detergent extracts  was determined using 
DEAE cellulose columns. In both assays nonsaturable binding, determined 
by including 5  ×  10  -7 M unlabeled mAb 35 in the binding reaction, con- 
stituted 10-20% of the total binding. Fractional occupancy was 70% at the 
concentration of 1251-mAb 35 used. 
fAb 35 Preparation 
mAb 35 fragment (fAb 35) containing the antigen binding site was prepared 
as described (Wan and Lindstrom, 1985).  mAb 35 (5 mg) in 0.50 ml of 10 
mM NaPO4,  pH 7.4,  with 100 mM NaCI and 10 nM sodium azide (PBS) 
was dialyzed  using 3,500  MW  cutoff spectrapor dialysis tubing (Spec- 
trum  Medical, Los Angeles, CA) for  18 h  at 4°C against PBS, pH  8.0, 
containing 1 mM EDTA and 25 mM 13-mercaptoethanol.  Sufficient papain 
was then added to achieve an ~1:1  molar ratio with the mAb 35, and, after 
4 h at 4°C, the digestion was terminated by adding 15 p.l of 1 M iodoacet- 
amide in PBS. After an additional 15 min, the reaction mixture was dialyzed 
against I0 mM NaPO4,  pH 7.5, overnight at 4°C.  fAb 35 was purified by 
ion exchange chromatography using a 5-ml DEAE column eluted with a 
0-0.5  M  gradient of NaCl  in  10 mM NaPO4,  pH 7.5.  fAb 35  is not re- 
tained by DEAE at low ionic strength, while mAb 35 is eluted with inter- 
mediate concentrations of salt. Column fractions were assayed for protein 
and ability to compete for ~251-mAb 35 binding, and were analyzed for the 
presence of undigested heavy chain using  SDS-PAGE according to  the 
method of Laemmli (1970). 
Antigenic Modulation 
Antigenic modulation of AChRs was achieved by incubating adrenal chro- 
marlin cell cultures with 7 nM mAb 35 for 24 h, unless otherwise indicated. 
Sucrose Gradient Centrifugation 
Cultures were scraped at 4°C in a solution containing 137 mM NaCI, 5.4 
mM KCI, 0.8  mM MgSO4,  1.3  mM NaPO4,  1.8 mM glucose, 2  mg/ml 
BSA, and 5 mM Hepes, pH 7.4, and centrifuged for 2 rain at 4°C in an Ep- 
pendorf microfuge at 15,600 g. The pellet was detergent extracted with 180 
p.l of 10 mM NaPO4,  pH 7.4,  containing 50 mM NaCI and 0.5%  Triton 
X-100 (homogenate buffer). Aliquots (0.15 ml) of extract were layered onto 
4.25-ml linear gradients of 5-20% sucrose in homogenate buffer. Centrifu- 
gation  was carried out at  60,000  rpm  for 60  min at 4°C  rotor (model 
Vti 65;  Beckman Instruments, Inc., Palo Alto, CA). Fractions of 0.2 ml 
were collected and either analyzed for radioactivity in the case of samples 
from cultures that had been prelabeled with J25I-mAb 35 or 125I-fAb  35, or 
assayed for mAb 35 binding using the DEAE column assay. The sedimenta- 
tion markers catalase (11.3 S) and bacterial alkaline phosphatase (6.1 S) were 
included in the same tube as the experimental sample. 
Catecholamine Release 
Catecholamine release was determined as previously described (Higgins 
and Berg,  1987).  Cells were preloaded with 3H-norepinephrine (3H-NE) 
for 2-3 h at 37°C and rinsed for 1 h. Release of the 3H-NE was induced 
either by 10  -6 M nicotine or by 54 mM K  ÷ in a 3-min test period. Radioac- 
tivity in aliquots of the media and of cell lysates obtained by scraping the 
cultures  in  0.6  N  NaOH  was analyzed by  liquid scintillation counting. 
3H-NE release is expressed as a percent of the radioactivity present in the 
cells before induced release. Basal release has been subtracted. The concen- 
tration of nicotine used was near the ECs0 for 3H-NE release (1.4 x  10  -6 M; 
Higgins and Berg,  1988a).  Using this protocol, nicotine-induced 3H-NE re- 
lease appears to be a linear function of the number of receptors occupied 
by agonist; antagonists compete for 3H-nicotine binding and block nico- 
tine-induced 3H-NE release with the same concentration dependence (Hig- 
gins and  Berg,  1988a).  Release  of preloaded catecholamines has  been 
shown to be an accurate index of release of endogenous catecholamines un- 
der the conditions used here (Mizobe et al.,  1979;  Kilpatrick et al.,  1980; 
Tri faro and Lee, 1980; Trifaro and Bourne, 1981; Role and Perlman, 1983). 
Affinity Alkylation 
Bovine adrenal chromaltin AChRs were affinity alkylated as described by 
Leprince (1983).  Briefly,  cultures were exposed to  1 mM dithiothreitol 
(DTT) for 15 min to reduce disulfide groups on the cells, washed, exposed 
to 1 mM bromoacetylcholine (BrACh) for 15 min to affinity  label reactive 
sulfhydryl moieties near the AChR agonist binding site, washed, oxidized 
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washed a final time. This protocol resulted in an 88  +  2% (n =  3) loss of 
nicotine-induced 3H-NE release, while no more than 2  -I- 9% (n =  3) loss 
was observed with control protocols in which the BrACh was either omitted 
or applied only after the reoxidation by DTNB. BrACh is an agonist for the 
bovine adrenal chromatfin AChR (data not shown). The blockade of AChR 
function after covalent attachment of the BrACh to the receptor may be 
caused by agonist-induced desensitization of the receptor or by the attached 
BrACh preventing reoxidation of a critical disulfide group on the receptor. 
Intracellular Recording 
The nicotine-induced membrane conductance (g.i¢) of bovine adrenal chro- 
maffin cells in culture was measured using single electrode intracellular 
recording techniques as described in the accompanying paper (Higgins and 
Berg,  1988b). 
Materials 
Bovine adrenal glands were obtained from Talone Packing Co. (Escondido, 
CA). mAb 35 was purified and radioiodinated to specific activities of 2-3 
×  10 '8 cpm/mol as previously described (Smith et al.,  1985).  fAb 35 was 
radioiodinated to a specific activity of 10 '~ cpm/mol by the same method. 
Neuronal bungarotoxin and ct-bungarotoxin were purified from Bungarus 
multicinctus  venom (Miami Serpentarium, Salt Lake City, UT) as previ- 
ously described (Ravdin et al.,  1981). Tunicamycin, puromycin, BrACh, 
DTNB,  and DTT were purchased from Sigma Chemical Co.  (St.  Louis, 
MO). Sephadex G-25 columns were purchased from Pharmacia Fine Chemi- 
cals (Piscataway,  NJ). Culture components and other reagents were obtained 
as previously described (Higgins and Berg,  1987, t988a). 
Results 
mAb 35-induced Loss of  AChRs 
Previous studies have shown that chronic exposure of bovine 
adrenal chromaffin cells to mAb 35 causes a loss of the nico- 
tinic response and a loss of AChR-related 3H nicotine bind- 
ing sites  from the  surface of the  cells  (Higgins and Berg, 
1987,  1988a).  Acute  exposure  to  antibody  fails  to  reveal 
competition between mAb 35 and nicotine for binding.  These 
results suggest that mAb 35 may slowly remove AChRs from 
the cell  surface by antigenic modulation as previously de- 
scribed for muscle AChRs (Heinemann et al.,  1977; Medic 
et al.,  1979a, b) and other surface proteins (Bourguinon and 
Singer,  1977; Taylor et al.,  1971; Stall  and Knopf,  1978). 
To  explore  the  possibility  of antigenic  modulation,  the 
effects of mAb 35 on AChR number and function were exam- 
ined further. Incubation of the ceils in 7 nM mAb 35 at 37°C 
induced a  time-dependent loss of AChR function, as  indi- 
cated by a decrease in nicotine-induced 3H-NE release from 
the cells (Fig.  1 A). In six experiments the loss occurred with 
a mean half-time of 5.5  +  1.1 h. The effect was specific since 
there was no decrement in the secretory response induced by 
54 mM K  ÷, and no decrement in basal release of 3H-NE or 
in ~H-NE uptake after a 24-h exposure to mAb 35 (data  not 
shown). 
The concentration dependence of the mAb 35 effect was 
examined by incubating cultures with antibody for 1 h to al- 
low  binding to  reach equilibrium.  The cultures  were then 
washed to remove unbound antibody and, after 18 h at 37°C, 
were tested  for a nicotinic response by measuring nicotine- 
induced 3H-NE release.  In parallel  experiments,  the num- 
ber of AChlLs on the cells was measured at the end of the in- 
cubation  by  quantitating  the  number  of '25I-mAb  binding 
sites.  This  strategy was feasible  because previously bound 
unlabeled mAb 35 should have dissociated during the  18-h 
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Figure 1. Time and concentration dependence of antigenic modula- 
tion. Cultures were incubated at 37°C either in 7 nM mAb 35 for 
the indicated times and then rinsed and assayed (A) or in the indi- 
cated concentrations of mAb 35 for 1 h at 37°C and then rinsed and 
incubated an additional 18 h without antibody before assay (B). In 
each case nicotine-induced 3H-NE release was measured and com- 
pared with that in untreated control cultures to calculate the percent 
loss of this response (solid circles) caused by the treatment. In B, 
~25I-mAb 35 binding was also measured since little if any unla- 
beled mAb 35 from the original incubation would have remained 
bound after  the  18-h period.  Again, the  levels of ~25I-mAb 35 
binding were compared to that obtained in untreated control cul- 
tures to calculate the percent loss (open triangles) induced by the 
treatment. Data represent the mean +  SEM of six experiments in 
A and four in B, each done with triplicate sets of cultures. Lines 
represent the best linear regression fit of data for nicotine-induced 
3H-NE release. 
incubation period:  '25I-mAb 35 dissociates from AChRs on 
the cells with a half-time of ,~2.4 h (see below). The results 
indicate  that  loss  of nicotinic response  from the  cells  as 
reflected  by  nicotine-induced  3H-NE  release  and  loss  of 
AChR number as reflected  by '25I-mAb 35 binding display 
similar dependences on the concentration of mAb 35 in the 
original binding incubation (Fig.  1 B). The parallel decline 
is consistent with the loss of function resulting from removal 
of AChRs from the cell  surface.  No loss of functional re- 
sponse was observed immediately after the initial  l-h incuba- 
tion with mAb 35, demonstrating that events  subsequent to 
antibody binding are required  for the effect. 
The loss of nicotinic response caused by mAb 35 depends 
both on temperature and the divalence of the antibody. Incu- 
bation with mAb 35 for 6 h at 37°C reduced the nicotinic re- 
sponse by more than half but had much less effect at 22°C 
and very little effect at 4°C (Fig. 2 A). Conditions that caused 
the complete loss of nicotinic response when mAb 35 was 
used as the antibody had no effect when the monovalent fAb 
35 was used instead  unless the fAb 35 was followed by goat 
anti-rat IgG (Fig.  2 B). A concentration offAb 35 was used 
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Figure 2. Dependence of antigenic modulation on temperature and 
divalence of antibody. (A) Cultures were incubated with 7 nM mAb 
35 for 6 h at the indicated temperature,  rinsed and transferred to 
37°C for 15 min, and then assayed for nicotine-induced 3H-NE re- 
lease. (B) Cultures were incubated for 24 h at 37°C with 7 nM mAb 
35, 20 nM fAb 35, or 20 nM fAb followed by a 1:500 dilution of 
goat  anti-rat antiserum  (GAR),  and  then  assayed  for nicotine- 
induced 3H-NE release. The concentration of fAb used achieved a 
fractional  site occupancy equivalent to that obtained  with 7 nM 
mAb 35 as determined by competition binding with ~25I-mAb  35. 
Results are presented as the percent of release obtained in untreated 
control cultures. Data represent the mean +  SEM of five experi- 
ments, each done with triplicate sets of cultures. 
for these experiments that gave the  same fractional occu- 
pancy as mAb 35 under the test conditions as determined by 
competition binding experiments. These results are consis- 
tent with AChRs being removed through antigenic modula- 
tion and suggest that aggregation of receptors in the plasma 
membrane may be necessary as a first step. 
The ability of mAb 35 to induce aggregation of AChRs in 
the plasma membrane was examined by determining the size 
of the receptor-antibody complex after detergent solubiliza- 
tion.  This approach was taken both because it offered the 
promise of a  direct demonstration of antibody-induced re- 
ceptor aggregation and because the density of AChRs on the 
cell surface was sufficiently low as to discourage immuno- 
fluorescent  studies  of receptor distribution  in  the  plasma 
membrane (Higgins and Berg, 1987). Al~alysis of solubilized 
AChRs by sucrose gradient centrifugation in the absence of 
antibody indicated a major species having a  sedimentation 
coefficient of 10.6 +  0.1  S (n  =  4; Fig. 3 A), similar to the 
•10  S value reported for AChRs from chick ciliary ganglion 
neurons (Smith et al.,  1985).  When  '25I-fAb 35 was used to 
label  AChRs  in  the plasma membrane of intact  cells,  the 
~25I-fAb-AChR  complex obtained  by  detergent  solubiliza- 
tion had a sedimentation coefficient of 11.2 +  0.1 S (n  =  3; 
Fig. 3 B). The slight increase presumably reflects the bind- 
ing of fAb 35 molecules to the receptor. Some free ~25I-fAb 
35 sedimenting at 3.9 S was also observed and is likely to 
represent antibody that had dissociated from receptor during 
the solubilization and centrifugation. In this and subsequent 
experiments an excess of unlabeled fAb was included during 
the cell homogenization to prevent binding of labeled anti- 
body or aggregation of receptors by antibody after solubiliza- 
tion.  Labeling surface AChRs with  t25I-mAb 35  instead of 
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Figure  3. Sucrose  gradient sedimentation  of AChRs detergent solu- 
bilized before and after exposure to antibody. Cells were either 
solubilized  in detergent  (A) or were first incubated with 20 nM 
~2sI-fAb 35 for 2 h at 37°C (B), or with 5 nM ~25I-mAb  35 for 2 h 
at either 37 (C) or 4°C (D) and then solubilized in detergent. The 
detergent extracts were fractionated by sucrose gradient sedimenta- 
tion, and fractions were collected and assayed for mAb 35 binding 
sites in the standard binding assay (A) or analyzed directly for radio- 
activity (B, C, and D). The major fast sedimenting species had S 
values of 10.3, 11.1, 14.6, and 12.6 in A, B, C, and D, respectively. 
The large amount of slowly sedimenting radioactivity, 4.6 S species 
in B and 6.8 S species in C and D, corresponds to free antibody in 
each case. Note that sedimentation was not allowed to proceed as 
far in Cas in the other cases (separate rotor runs) to avoid centrifug- 
ing the large species to the bottom of the tube. LeJi arrows, catalase 
(11.3 S); right arrows, bacterial alkaline phosphatase (6.1 S). Simi- 
lar results were obtained in two to five additional experiments for 
the various conditions. 
~25I-fAb 35 resulted in antibody-receptor complexes with a 
different sedimentation profile when solubilized.  A mixture 
of large components was usually observed; the major species 
had a sedimentation coefficient ranging from 12.6 to >17.0 S 
among experiments (Fig.  3  C),  with a mean value of 14.8 
+  0.5  S  (n  =  8).  In addition  some free  ~25I-mAb 35  was 
present, sedimenting at 6.8 S, again presumably due to dis- 
sociation of the antibody-receptor complex. The large anti- 
body-receptor species must have formed in the plasma mem- 
brane because the excess of unlabeled fAb 35 present during 
the cell homogenization  would have prevented subsequent 
'25I-mAb  35  binding  and  cross-linking  of AChRs.  Since 
mAb 35  is divalent and the bovine chromaffin AChR may 
have more than  1 mAb 35  binding  site,  the large species 
could represent either cross-linked receptors or single recep- 
tors with multiple antibodies bound. To distinguish between 
these possibilities,  cells  were labeled  with  '2SI-mAb 35  at 
4°C where membrane fluidity may be sufficiently reduced as 
to prevent aggregation of receptors from occurring.  These 
conditions have been shown to permit binding of ~25I-mAb 
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induced 3H-NE release (Higgins and Berg,  1987), presum-  ~  so 
ably because antigenic modulation is blocked. After binding 
an  amount of labeled  mAb  35  at 4°C  equivalent to that  ~  6o 
achieved at 37°C, the antibody-receptor complex was solubi-  ~_  4o 
lized and shown by sucrose gradient centrifugation to have  ~:  c~ 
a sedimentation coefficient of 12.7  +  0.4 S (n  =  8) (Fig. 3 
D).  This  value is  lower than  that obtained for antibody-  ~  2o 
receptor complex formed at 37°C and indicates that the latter 
is likely to represent AChR aggregates induced by divalent 
antibodies.  Apparently  mAb  35  aggregates  AChRs  in  the  -~  ra 
membrane at 37°C, while fAb 35 at 37°C and mAb 35 at 4°C 
are not able to do so. The conditions required for receptor 
cross-linking are, therefore, the same as those required for 
antibody-induced loss of surface AChRs from the cells. 
The Fate of  Bound mAb 35 
If  mAb  35  drives  the  internalization  of surface  AChRs 
through antigenic modulation, bound antibody may be inter- 
nalized with the receptor and subsequently degraded in lyso- 
somes. This possibility was examined by following the fate 
of t25I-mAb 35 bound to surface AChRs on the cells. Sam- 
pling the culture medium at various times after binding ~25I- 
mAb 35 to the cells indicated that radioactivity was released 
with biphasic kinetics. The rapidly dissociating component 
displayed a half-time of 2.4  +  0.1 h (n  =  3). Gel filtration 
of culture media using a Sephadex G-25 column indicated 
that the rapidly released radioactivity was associated with 
material appearing in the void volume, as expected for intact 
antibody that dissociated from receptor (data not shown). 
The slowly dissociating component was a candidate for inter- 
nalized antibody that had been degraded and released as ra- 
diolabeled fragments.  The relative proportion of the slow 
component depended on how  long the cultures had been 
incubated originally in ~25I-mAb 35. Longer times produced 
a greater proportion of slow component, consistent with a 
time-dependent internalization of bound antibody. To study 
the slow component in isolation, cultures were incubated in 
7 nM  t25I-mAb 35 for 6 h, rinsed, incubated another 18 h 
without antibody, and rinsed again to eliminate the rapidly 
dissociating component, and then examined for subsequent 
release of radioactivity (Fig. 4).  At 37°C the loss was  de- 
scribed by a single exponential function with a half-time of 
6.8 h. This value is similar to that obtained for degradation 
of AChRs in the muscle cell line BC3H-I in the presence of 
anti-AChR antibodies (Lindstrom and Einarson,  1979). At 
4°C the component had a half-time of 36 h, demonstrating 
a strong temperature dependence. Chloroquine, an inhibitor 
of proteolysis in lysosomes, also greatly decreased the rate 
at which radioactivity was lost from the cells (Fig. 4), imply- 
ing  that  lysosomal  proteolysis  may  be  essential  for  the 
process. 
Gel filtration with Sephadex G-25 columns indicated that 
much of the  slowly released  radioactivity was  associated 
with  small molecular weight material.  Cells were labeled 
with 5 nM  ~25I-mAb 35 for 6 h, rinsed,  incubated another 
18 h without antibody, rinsed again, and then incubated for 
8 h more at 37°C to collect released radioactivity in the cul- 
ture medium. Most of the released radioactivity (74 +  12 %, 
n =  4) migrated in the included volume of the column. Con- 
trol experiments indicated that the  remainder represented 
dissociation of nonspecifically bound antibody. Radioactiv- 
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Figure 4.  Loss of radioactivity from cells after binding t25I-mAb 
35. Cultures were incubated in 7 nM t25I-mAb 35 for 6 h, rinsed, 
incubated for an additional 18 h without antibody, rinsed again, and 
then assayed for radioactivity retained by the cells as a function of 
time at 37°C (solid circles), 4°C (open circles), or 37°C in the pres- 
ence of 100 ~tM chloroquine (solid inverted triangles). Data repre- 
sent the mean of three experiments done with triplicate sets of cul- 
tures and are shown as a percent of the radioactivity present at the 
outset. SEMs were x<9% of the values shown. 
ity remaining with the cells at the end of the incubations was 
excluded by the column after solubilization. These results are 
consistent with antigenic modulation of surface AChRs by 
mAb 35 in which the antibody binds to surface AChRs, in- 
duces receptor aggregation and internalization, and then is 
degraded  in  the  lysosomes to  release  small  radiolabeled 
products into the medium. 
Rate of  AChR Appearance 
The rate of AChR appearance in the plasma membrane was 
determined in two ways. In the first case mAb 35 was used 
to remove surface AChRs by antigenic modulation.  Reap- 
pearance ofmAb 35 binding sites was then taken to represent 
accumulation of new AChRs on the cell surface. The initial 
rate of reappearance after antigenic modulation was equiva- 
lent to 2.8 % of the number of receptors on cells in control 
cultures per hour (Fig. 5). No initial lag in the recovery was 
observed, consistent with the finding that antigenic modula- 
tion does not deplete the internal pool of AChRs, which pre- 
sumably includes AChRs in transit to the surface (Higgins 
and Berg,  1988a). When puromycin was added to the cul- 
tures 4 h before initiation of the recovery period, no AChRs 
appeared (data not shown), demonstrating a requirement for 
protein synthesis in the recovery process. 
The second approach involved blocking surface receptors 
with fAb 35, which does not induce antigenic modulation, 
and  then  measuring  the  appearance  of new  AChRs  with 
~2~I-mAb 35. To correct for a contribution from preexisting 
surface AChRs from which the fAb might dissociate during 
the experiment, sister cultures were maintained in puromy- 
cin  to block protein synthesis or in tunicamycin to block 
glycosylation of receptors. The drug treatments were begun 
3.5 h before adding fAb 35 so that insertion of new receptors 
would be completely blocked during the period of interest 
(Stollberg and Berg, 1987). The appearance of ~zSI-mAb 35 
binding sites under these conditions was taken to represent 
sites  exposed by  lab  dissociation.  Subtracting  such  sites 
from the total sites measured in the absence of  drug treatment 
yielded a value for the initial rate of AChR reappearance as 
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Figure 5. Appearance of AChRs on the cell surface after antigenic 
modulation. Surface AChRs were removed from cells by incubating 
cultures  for 24 h with 7 nM mAb 35. After rinsing,  the cultures 
were assayed for reappearance of mAb 35 binding sites using t2sI- 
mAb 35. The data were corrected for competition by residual unla- 
beled mAb 35 left over from the original  incubation.  Values are 
expressed  as a percent of the number of sites present in untreated 
control cultures (100%  =  6.0  5- 0.3  fmol/culture)  and represent 
the mean  5- SEM of five experiments  done with triplicate  sets of 
cultures. 
being 3.6%  of the number of receptors present on cells in 
control cultures per hour (Fig.  6). 
Rate of  AChR Degradation 
The rate of AChR loss from the surface of the cells in the 
absence of antigenic modulation was determined by blocking 
the appearance  of new AChRs with  either  tunicamycin or 
puromycin,  and then  measuring  the  number  of remaining 
AChRs as a function of time.  The concentrations of tunica- 
mycin and puromycin used blocked >98 % of the incorpora- 
tion of 3H-mannose or 3H-leucine,  respectively,  into TCA 
precipitable material.  AChRs, as measured by ~25I-mAb 35 
binding sites, were lost from the surface of the cells by a first 
order process with a  half-time of 23.7  +  0.3 h  (n  =  3) in 
puromycin (Fig. 7 A), and 23.4 -1- 0.8 h (n =  3) in tunicamy- 
cin (Fig.  7 B).  In puromycin a lag of 3.2  +  0.6 h  was ob- 
served preceding the loss of surface AChRs; in tunicamycin 
the lag was 2.8  +  0.3 h.  The 3-h lag is likely to represent 
the transit time for newly synthesized AChRs to reach and 
be inserted into the plasma membrane. In the case of tunica- 
mycin treatment,  the decline in nitotinic response was also 
determined, using nicotine-induced 3H-NE release as an as- 
say. After a lag of 3.0 +  0.3 h (n =  3), the response declined 
with a half-time of 25.4 +  2 h (Fig. 7 B), in good agreement 
with the loss of surface receptors measured by ~25I-mAb 35 
binding. The cells appeared to be viable after the tunicamy- 
cin treatment since the amount of 3H-NE uptake,  basal 3H- 
NE release,  and K+-induced aH-NE release were similar to 
the levels measured in untreated sister cultures. Comparable 
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Figure 6. Appearance of new 
AChRs on the cell surface af- 
ter blockade of existing AChR 
sites by fAb 35. Cultures were 
incubated  with a near saturat- 
ing  concentration of fAb 35 
(100 nM) for 90 min to block 
existing  receptors,  and  then 
were  rinsed  and  assayed  for 
the  appearance  of new  'Z~l- 
mAb 35 binding sites at the in- 
dicated  times.  Corrections 
were made for fAb dissocia- 
tion during the time course of 
the  experiment  which would 
have exposed sites on preexist- 
ing receptors.  This was evaluated by carrying out parallel determi- 
nations on sister cultures  in which the appearance of new sites was 
blocked by treating the cells either with 20 ~tg/ml puromycin or with 
1 lxg/ml tunicamycin beginning 3.5 h before addition offAb 35. Ap- 
pearance  of  '2SI-mAb 35  binding  sites  in  such  cultures  ranged 
from 20 to 80% of the total sites obtained over the 4-h time period 
in the absence of puromycin and tunicamycin,  and were subtracted 
to yield the values  shown.  The high rate of fAb dissociation  pre- 
vented longer times from being examined. The results are expressed 
as a percent of the sites present  on untreated  cells  and represent 
the mean  +  SEM of five experiments  done with triplicate  sets of 
cultures. 
experiments  in  puromycin  were  not  meaningful  because 
chronic blockade of protein synthesis impaired the release 
process independent of effects on AChRs. The half-times of 
AChR  loss  measured  either  as  a  decline  in  l:5I-mAb 35 
binding sites or as a decline in nicotinic response from the 
cells,  corresponds to an initial  rate of loss of 2.8 %  of the 
receptors per hour. 
Since the number of AChRs on bovine adrenal chromaffin 
cells in culture does not change over the time period exam- 
ined (3-10 d  in culture;  Higgins and Berg,  1987),  the rate 
of receptor appearance must equal the rate of receptor loss 
from the surface. In agreement with this prediction,  the ex- 
perimentally observed rates both of AChR appearance and 
of AChR loss are ~3 % per hour. This corroborates, in part, 
the separate procedures used to measure AChR appearance 
and degradation. 
Reappearance of  AChR Function 
Recovery of nicotinic response would be expected to coin- 
cide with recovery of AChR number on the surface of adrenal 
chromaffin cells after antigenic modulation. To examine this, 
recovery of nicotine-induced 3H-NE release was measured 
at various times after antigenic modulation had been used to 
remove the surface AChRs initially present. As shown in Fig. 
8, recovery of nicotine-induced 3H-NE release under these 
conditions can be described as a single exponential process 
with a half-time of 8.9 h and an initial recovery rate of 9%/h. 
This is much more rapid than the reappearance of AChRs on 
the surface of the cells which recovers to control levels with 
a  half-time of ",,24 h  and an initial  rate of "-,3%/h. 
To corroborate  the  rapid  recovery  of the  functional  re- 
sponse,  a  second method was devised.  In this case AChRs 
on the surface of the cells were irreversibly blocked by affi- 
nity alkylation as previously described for AChRs on PCI2 
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Figure 7. Loss of ACBRs during blockade of either protein synthesis 
or  glycosylation.  Cultures  were  incubated  in  either  20  Ixg/ml 
puromycin (A) or 1 txg/ml tunicamycin  (B) and assayed at the indi- 
cated times for 12SI-mAb  35 binding (solid circles)  or for nicotine- 
induced  3H-NE release  (open circles).  Values are expressed  as a 
percent of the receptors present at the outset and represent the mean 
+  SEM of three experiments,  each done with triplicate  sets of cul- 
tures.  After  an  initial  lag,  the  number  of AChRs  on  the  cells 
declined with first order kinetics and a half-time  of 23.7 h in A and 
23.4 h in B. The lag period, determined by extrapolating  the best 
fit of the exponential  decay phase back to 100%,  was found to be 
3.2 h in A and 2.8 h in B. The lag period presumably reflects the 
time required for appearance of new receptors to be blocked; no in- 
crease is expected during the lag since the number of AChRs on the 
cells is normally at steady-state (Higgins and Berg,  1987). The loss 
of nicotine-induced  3H-NE release  in the presence of tunicamycin 
occurred with a half-time  of 25.4 h after a lag of 3.0 h. 3H-NE re- 
lease  in response to 54 mM K  + was not affected by tunicamycin 
treatment  over the time course examined  (data not shown). 
cells (Leprince,  1983).  The procedure involved using DTT 
to reduce disulfide moieties on the surface of the cells, then 
reacting the cells with  BrACh which preferentially  couples 
covalently to a sulthydryl moiety near the active site of AChRs, 
and finally reoxidizing the cell surface with DTNB to recon- 
struct unreacted disulfides.  Preexisting AChRs are blocked 
irreversibly  under these  conditions:  the nicotinic  response 
does not recover when protein synthesis is inhibited (data not 
shown).  Accordingly,  the  reappearance  of a  nicotinic  re- 
sponse  must  reflect  new  receptors  being  inserted  into  the 
plasma membrane.  Applying the procedure to bovine adre- 
nal chromaffin cells in culture (Fig. 8) produces a half-time 
of 8.1  +  0.9 h (n =  4) for recovery of the nicotinic response 
with an initial  recovery rate of 8.5%/h,  in good agreement 
with  recovery obtained after antigenic modulation. 
The surprising finding that the nicotinic response returns 
to control levels more quickly than does the number of sur- 
face  AChRs  raises  questions  about  the  measurement  of 
receptor function. Both the dependence on agonist concen- 
tration  and the time course of nicotine-induced  3H-NE re- 
lease, however, are indistinguishable for AChRs on unmodu- 
lated cells and those on cells after half maximal  recovery; 
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Figure  &  Recovery  of nicotinic  response  after  either  antigenic 
modulation or blockade of receptors by affinity alkylation.  Cultures 
were either incubated with 7 nM mAb 35 for 24 h to remove AChRs 
by .antigenic modulation (solid circles)  or were affinity alkylated 
with BrACh to block the activation of  existing AChRs (open inverted 
triangles), and then were rinsed  and assayed for nicotine-induced 
3H-NE release  at the indicated  times.  Values are expressed  as a 
percent of those obtained in untreated control cultures and represent 
the mean  +  SEM of three to four experiments,  each done with 
triplicate  sets of cultures.  3H-NE release  induced by 54 mM K  + 
was unaffected by the treatments  (data not shown). (Inset) Semi-log 
plot of recovery rate indicates a first order process.  Only values ob- 
tained during the first 2 h were used to calculate  the initial  rate of 
recovery; they were assumed to follow a zero order process. 
i.e.,  8 h after antigenic modulation (Fig. 9). In addition, the 
assays reveal no change in rates of agonist-induced receptor 
desensitization  as  reflected  by declining  3H-NE release  in 
response to high concentrations of agonist (Fig. 9 B), though 
a change in a rapid component of desensitization would have 
gone undetected.  Lastly,  there  is  no  evidence  for "spare" 
receptors in the release assay: the loss of surface AChRs with 
time in tunicamycin closely matches the decline in nicotine- 
induced 3H-NE release from the cells (Fig. 7 B). Similarly, 
no evidence for spare AChRs was obtained  in experiments 
where the ability of neuronal bungarotoxin or classical an- 
tagonists to block the nicotinic response was compared with 
their ability to compete with 3H-nicotine for binding to the 
cells (Higgins and Berg,  1988a).  These results suggest that 
AChRs newly inserted into the plasma membrane are more 
active in some way than are older AChRs. 
Intracellular  recording  corroborates  the  results  of  the 
3H-NE release assay, showing that new AChRs appear to be 
more  functional  than  old  AChRs.  Cells  with  new  AChRs 
were obtained by removing AChRs with antigenic modula- 
tion and then allowing the cells to recover for 6-8 h, during 
which time new AChRs appeared in the plasma membrane. 
Though such cells had only '~20% of the AChRs present on 
untreated control cells (Fig. 5), they had ",,70% of the nico- 
tinic response.  The gnic value was 26  +  3  nS (n  =  24) for 
treated cells compared with 37  +  6 nS (n =  32) for control 
cells.  In contrast,  ceils maintained  in tunicamycin for 27 h 
had  ,~,50%  of the  AChRs  initially  present  (Fig.  7  A)  and 
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Figure 9. Agonist concentration and time dependence  of nicotine- 
induced 3H-NE release after recovery from antigenic modulation. 
Nicotine-induced  3H-NE  release was  examined with  untreated 
cells (solid circles) and with cells that had been antigenically modu- 
lated by incubation with 7 nM mAb 35 for 24 h and then allowed 
to recover for 8 h (open squares). The time of exposure to the stan- 
dard concentration of 10  -6 M nicotine was varied as indicated in A 
while the concentration  of nicotine in the standard 3-min release 
period was varied as indicated in B. The only difference observed 
between the two kinds of cultures in the assays is that unmodulated 
cells had a larger response to agonist. Values are expressed as a per- 
cent  of the  3H-NE present  in  cells  at the  beginning  of the  test 
period and represent the mean +  SEM of three experiments, each 
done with triplicate sets of cultures. 
•54%  of the nicotinic response compared to untreated con- 
trol cells. The g,~ value was 20 ___ 3 nS (n  =  31) for treated 
cells  in  this  case.  The  results  indicate  a  two-to-threefold 
difference in the relative nicotinic responses of new and old 
AChR populations defined in this way. 
Discussion 
The major findings reported here are that (a) AChRs can be 
removed from the surface of bovine adrenal chromaffin cells 
by antigenic  modulation,  (b) in the absence of modulation 
the AChRs  have a  half-life of "-~24 h  in  the plasma mem- 
brane, and (c) newly inserted AChRs appear to be more ac- 
tive than older receptors in  the plasma membrane. 
Antigenic  modulation  has  been  widely  documented  for 
membrane proteins and can occur when divalent antibodies 
induce clustering of surface molecules in the plasma mem- 
brane. The clustered components are then internalized and 
degraded by the cell (Bourguinon and Singer,  1977).  The evi- 
dence for antigenic modulation of AChRs on bovine adrenal 
chromaffin cells by mAb 35 is substantial.  Previous studies 
indicated that chronic exposure to mAb 35 induces the loss 
of high affinity 3H-nicotine binding sites from the surface of 
the  cells,  though  mAb 35 does not compete with  nicotine 
for binding (Higgins and Berg,  1988a).  The present studies 
demonstrate that the agonist response as measured by nico- 
tine-induced release of 3H-NE and the number of AChRs on 
the surface as measured by '25I-mAb 35 binding are removed 
in parallel after exposure to mAb 35. The removal is depen- 
dent on events that occur subsequent to antibody binding, 
and the process is dependent on time, temperature, and the 
concentration and divalence of mAb 35. mAb 35 induces ag- 
gregation of AChRs in the plasma membrane, and some of 
the bound antibody is apparently internalized,  degraded to 
small molecular weight material, and released into the cul- 
ture medium. This latter process is also temperature depen- 
dent  and  can  be blocked  by  chloroquine,  an  inhibitor  of 
lysosomal proteolysis. All of these characteristics are consis- 
tent with antigenic modulation of the AChR by mAb 35. 
Anti-AChR  antibodies dramatically  increase the  rate of 
degradation  of muscle  AChRs  (Heinemann  et  al.,  1977; 
Drachman et al.,  1978;  Merlie et al.,  1979a,  b) and, as a 
result, cause a reduction in miniature endplate potential am- 
plitude and in sensitivity to ACh (Albuquerque et al., 1976). 
Antigenic modulation of muscle AChRs by anti-receptor an- 
tibodies has been advanced as a contributing factor in my- 
asthenia gravis (Lindstrom and Einarson,  1979). Since mAb 
35 recognizes the main immunogenic region of the AChR, 
as do most of the antibodies in the serum of patients with my- 
asthenia gravis (Tzartos et al.,  1982), it is possible that anti- 
genic modulation of adrenal chromaffin AChRs may have rel- 
evance for symptoms of the disease as well.  The ability of 
mAb 35 to bind but not antigenically  modulate AChRs on 
chick ciliary ganglion neurons in the absence of secondary 
antibodies (Halvorsen and Berg,  1987)  implies that ciliary 
ganglion AChRs differ in some way from AChRs on bovine 
adrenal chromaffin cells.  Ciliary ganglion neurons are not 
refractory to internalization of membrane components per se 
in  culture  (Ravdin et al.,  1981). 
Antigenic  modulation  was  used  in  the  present  study  to 
clear the cell surface of AChRs so that appearance of new 
AChRs could be measured. This, together with several meth- 
ods for examining receptor appearance and degradation, in- 
dicated a value of ~  24 h  for the half-life of AChRs in the 
plasma membrane of bovine adrenal chromaffin cells. Simi- 
lar values have been obtained for AChRs of vertebrate skele- 
tal muscle (Devreotes and Fambrough,  1975;  Devreotes et 
al.,  1977)  and  chick  ciliary  ganglion  neurons  in  culture 
(Stollberg and Berg,  1987). Since the number of AChRs per 
cell does not change over the culture ages used in the present 
experiments (Higgins and Berg,  1987),  the rate of appear- 
ance of new receptors in the plasma membrane must equal 
the rate of receptor degradation. Consistent with this predic- 
tion,  the hourly rate of receptor appearance as determined 
by two independent methods was equivalent to '~3 % of the 
number  of receptors  present  on  the  cells  at  equilibrium, 
and the rate of degradation,  measured separately, was also 
'~3%/h. 
The 3-h lag that precedes loss of surface AChRs when the 
appearance of new  receptors is blocked by tunicamycin or 
puromycin is likely to represent the period during which pre- 
viously synthesized intracellular AChRs are transported to 
and  inserted  into  the  plasma  membrane.  Bovine  adrenal 
chromaffin cells from mature animals have an intracellular 
pool of AChRs that comprise ~20% of the total AChRs (Hig- 
gins and Berg,  1988a).  The measured lag time and rate of 
insertion predict that about half of the intracellular receptors 
are destined to reach the surface. Even larger pools of inter- 
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and Berg,  1987) and Na channel ct subunits (Schmidt et al., 
1985) have been reported in other systems. 
The  most  surprising  finding  was  that  the  nicotinic  re- 
sponse of the cells recovered more rapidly than the surface 
complement of AChRs. Four possible explanations are con- 
sidered  here:  (a) the assay for nicotinic response may not 
have been proportional to the number of AChRs,  (b) mAb 
35 binding sites may have included a substantial non-AChR 
population with a slow rate of appearance, (c) recovery of the 
response may have included a contribution from receptors 
previously on the cell surface, or (d) new and old AChRs in 
the plasma membrane may differ  with respect to function. 
Several lines of evidence argue against the first explanation. 
Antigenic modulation of surface AChRs by mAb 35 caused 
a parallel decline in the number of AChRs and in the nico- 
tinic response of the cells.  Tunicamycin treatment caused a 
similar parallel decrease.  These observations indicate that 
few spare receptors exist on the cells,  at least with respect 
to the 3H-NE release  assay.  No changes were observed  in 
either the time course of release  or in the dependence on 
agonist concentration when the release assay was performed 
on cells  recovering  from antigenic modulation.  Lastly,  re- 
sults obtained with intracellular recording techniques cor- 
roborated those obtained with the 3H-NE release assay.  The 
second explanation is equally unlikely. ~25I-mAb 35 binding 
studies reveal a single class of high affinity binding sites on 
the cells, and the binding component has the properties ex- 
pected for the AChR (Higgins and Berg,  1987).  Moreover, 
the number of ~2SI-mAb 35 binding sites is in good agree- 
ment with the number of high affinity 3H-nicotine binding 
sites  representing  AChRs  on the cells  (Higgins  and Berg, 
1988a). In addition, the rates of appearance and disappear- 
ance of mAb 35 sites followed zero and first order kinetics, 
respectively, as expected for a single population of sites. The 
third possibility is also improbable.  Bound antibody is de- 
graded,  strongly suggesting internalization of receptors.  In 
addition, AChR-associated  3H-nicotine  binding sites  are com- 
pletely removed from the cell surface after mAb 35 treatment 
(Higgins and Berg, 1988a). Receptor recycling after removal 
of bound antibody is unlikely since recovery of the nicotinic 
response does not occur in the presence of protein synthesis 
inhibitors,  a  treatment  which does  not block  insertion of 
AChRs  into the plasma  membrane  that have already been 
synthesized. These considerations point to the fourth expla- 
nation and suggest that newly inserted AChRs are  under a 
unique regulatory control or are different from older AChRs 
with respect to function. The accompanying paper supports 
this  interpretation  and  demonstrates  that  not  only  can  a 
cAMP-dependent process enhance the nicotinic response of 
the cells,  but that it can discriminate between new and old 
AChRs in the plasma membrane when doing so (Higgins and 
Berg,  1988b). 
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